drugset / Trial / NCT01872611
Nepafenac Once Daily for Macular Edema - Study 2
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
Timeline
- Start
- 2013-06
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nepafenac | Other / unclassified | 0.3 % | Topical |
| Background | Prednisolone | Other / unclassified | — | Topical |